ProfileGDS4814 / ILMN_1732885
TitleOvarian cancer xenograft tumor response to trastuzumab and pertuzumab
OrganismHomo sapiens


none trastuzumab pertuzumab trastuzumab and pertuzumab GSM780707 GSM780708 GSM780709 GSM780719 GSM780720 GSM780721 GSM780710 GSM780711 GSM780712 GSM780722 GSM780723 GSM780724 GSM780713 GSM780714 GSM780715 GSM780725 GSM780726 GSM780727 GSM780716 GSM780717 GSM780718 GSM780728 GSM780729 85% 82% 82% 85% 83% 82% 82% 85% 84% 82% 85% 84% 85% 82% 85% 85% 83% 84% 84% 85% 85% 85% 85% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM780707Untreated after 4 days (C1_1)233.71585
GSM780708Untreated after 4 days (C2_1)180.14482
GSM780709Untreated after 4 days (C3_1)168.76582
GSM780719Untreated after 4 days (C1_2)231.72985
GSM780720Untreated after 4 days (C2_2)194.70783
GSM780721Untreated after 4 days (C3_2)177.70982
GSM780710Trastuzumab treated after 4 days (T1_1)169.47382
GSM780711Trastuzumab treated after 4 days (T2_1)234.78985
GSM780712Trastuzumab treated after 4 days (T3_1)204.02384
GSM780722Trastuzumab treated after 4 days (T1_2)175.64782
GSM780723Trastuzumab treated after 4 days (T2_2)231.42485
GSM780724Trastuzumab treated after 4 days (T3_2)214.92984
GSM780713Pertuzumab treated after 4 days (P1_1)226.5185
GSM780714Pertuzumab treated after 4 days (P2_1)175.64782
GSM780715Pertuzumab treated after 4 days (P3_1)227.72585
GSM780725Pertuzumab treated after 4 days (P1_2)240.74585
GSM780726Pertuzumab treated after 4 days (P2_2)194.01583
GSM780727Pertuzumab treated after 4 days (P3_2)211.1584
GSM780716Trastuzumab and Pertuzumab treated after 4 days (TP1_1)205.03884
GSM780717Trastuzumab and Pertuzumab treated after 4 days (TP2_1)223.43485
GSM780718Trastuzumab and Pertuzumab treated after 4 days (TP3_1)220.04385
GSM780728Trastuzumab and Pertuzumab treated after 4 days (TP1_2)227.72585
GSM780729Trastuzumab and Pertuzumab treated after 4 days (TP2_2)220.7985